LigaChem Biosciences Inc.

KOSDAQ:A141080 Stock Report

Market Cap: ₩4.4t

LigaChem Biosciences Past Earnings Performance

Past criteria checks 0/6

LigaChem Biosciences's earnings have been declining at an average annual rate of -32.8%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 6.8% per year.

Key information

-32.8%

Earnings growth rate

-31.9%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate6.8%
Return on equity-0.5%
Net Margin-2.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Dec 21
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%

Nov 29
Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%

LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 09
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money

May 23
Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money

A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

Mar 29
A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?

Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

Dec 07
Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

Revenue & Expenses Breakdown

How LigaChem Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A141080 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24101,417-2,93217,48698,611
30 Jun 2476,216-33,94713,05998,611
31 Mar 2457,543-46,54320,06379,586
31 Dec 2334,146-73,70417,24879,609
30 Sep 2334,470-83,05325,24771,490
30 Jun 2335,643-71,78415,88771,490
31 Mar 2335,266-54,33616,81859,986
31 Dec 2233,412-45,09215,43751,110
30 Sep 2241,783-5,1735,62433,942
30 Jun 2239,789-5,443-5,97143,719
31 Dec 2132,157-23,3914,70739,071
31 Dec 1957,50013,5867,97716,711
30 Sep 1951,280-1,0735,51814,290
30 Jun 1929,947-24,2205,03716,807
31 Mar 1928,452-23,1974,95715,533
31 Dec 1825,240-25,7704,85615,505
30 Sep 1824,869-15,2215,75613,629
30 Jun 1823,907-10,5985,6588,894
31 Mar 1823,177-12,0347,7016,907
31 Dec 1722,057-12,9345,8159,263
30 Sep 1720,790-15,7465,2889,072
30 Jun 1718,845-15,8905,1638,841
31 Mar 1717,541-16,1833,37011,355
31 Dec 1616,655-14,7255,0227,813
30 Sep 1613,720-8,3304,5617,576
30 Jun 1610,294-8,1923,4277,310
31 Mar 166,295-7,6712,3326,680
31 Dec 151,788-8,2372,0947,000
31 Dec 14870-8,6861,6057,679

Quality Earnings: A141080 is currently unprofitable.

Growing Profit Margin: A141080 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A141080 is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.

Accelerating Growth: Unable to compare A141080's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A141080 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (39.6%).

Return on Equity

High ROE: A141080 has a negative Return on Equity (-0.46%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 02:59
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LigaChem Biosciences Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mujinn LeeCape Investment & Securities Co., Ltd.
Seohyun LeeCitigroup Inc
Jisoo LeeDAOL Investment & Securities Co., Ltd.